2006 Guide to psychiatric drug interactions

Primary Psychiatry

Volumn 13, Issue 4, 2006, Pages 35-64

  Preskorn, Sheldon H ^a,b   Flockhart, David ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b University of Montreal   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; AMPRENAVIR PHOSPHATE; ANTIDEPRESSANT AGENT; ATAZANAVIR; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; DULOXETINE; ERYTHROMYCIN; ESZOPICLONE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; GENERIC DRUG; ITRACONAZOLE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEFAZODONE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PROPAFENONE; QUETIAPINE; QUINIDINE; RAMELTEON; RITONAVIR; TELITHROMYCIN; UNINDEXED DRUG;

AUTONOMIC DYSFUNCTION; CONFUSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MEDICAL LIABILITY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PRESCRIPTION; REVIEW; SIDE EFFECT; UNITED STATES;

EID: 33646388393     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Voltaire 1694-1788.
2. Bear RB, Osier VK. Aphorisms: from His Bedside Teaching and Writings. Springfield, IL: Charles C. Thomas; 1951.
3. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
4. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277(21):682.
5. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci. 1998;48(3):383-386.
6. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psych Prac. 2002;8(4):233-238.
7. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand. 1997;96(5):379-384.
8. Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry. 1993;38:62-63.
9. Azaz-Livshits TL, Danenberg HD. Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry. 1997;30(6):274-275.
10. Beasley-CM J, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacoi. 1993;13(5):312-320.
11. Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265.
12. Preskorn SH. I don't see 'em. J Prac Psych and Behav Hlth. 1997;3(5):302-307.
13. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother. 2002;36(3):440-443.
14. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol. 1999;13(3):313-317.
15. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. Am Pharmacother. 2000;34(12):1406-1409.
16. Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):783-792.
17. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22(4):419-423.
18. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf. 1991;6(6):460-462.
19. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15-27.
20. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22(1):46-54.
21. Ludgate J, Keating J, O'Dwyer R, Callaghan N. An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neurol Scand. 1985;71(6):448-452.
22. Preskorn SH. Do you believe in magic? J Prac Psych and Behav Hlth. 1997;3(2):99-103.
23. Preskorn SH. A message from Titanic. J Prac Psych and Behav Hlth. 1998;4(4):236-242.
24. Bertschy G, Baumann PA, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994;16:42-45.
25. Preskorn SH. Applied Clinical Polypharmacology. Polypharmacology Columns. Available at: www.preskorn. com/columnl.html. Accessed January 17, 2006.
26. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol. 1997;53(1):7-11.
27. Bjerrum L, Segaard J, Hallas J, Kramer A. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol. 1998;54(3):197-202.
28. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull. 1998;45(2):210-213.
29. Oavies SJC, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004;57(4):464-472.
30. PRN prescribing in psychiatric inpatients-potential for pharmacokinetic drug interaction. Presented at 9th International Meeting of Clinical Pharmacology in Psychiatry; Sep. 24-27:2005; Oxford, England.
31. Bergendal L, Friberg A, Schaffrath A. Potential drug-ding interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci. 1995;17(5):52-157.
32. Preskorn SH. Drug-Drug interactions: Proof of relevance J Psych Prac. 2005;11(2):116-122.
33. Preskorn SH. Drug-Drug Interactions: Proof of relevance (Part II): Cause of tolerability problems or noncompliance. J Psych Prac. 2005;11(6):397-401.
34. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089-1096.
35. Flockhart OA. Drug Interactions. Available at http://medicine.iupui.edu/ flockhart/. Accessed January 17, 2006.
36. Preskorn SH, Catterson ML. General principles of pharmacokinetics. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, eds. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag; 2004:35-86.
37. Preskorn SH, Flockhart 0.2004 Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2004;11(2):39-60.
38. Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psyctiiatr Pract. 2003;9(3):228-236.
39. Diamond MC, Johnson RE, Ingham CA. Morphological changes in the young adult and aging rate cerebral cortex, hippocampus, and diencephalon. Behav Biol. 1975;14(2):163-174.
40. EIi Lilly & Co. Duloxetine (Cymbalta). Available at: http://eli.lilly.com/us/cymbalta-pi.pdf. Accessed January 17, 2006.
41. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170-177.
42. Preskorn SH, Baker B, Klick-Davis A, et al. The effect of duloxetine, escitalopram, and sertraline on CYP 2D6 function. Clin Pharm Ther. 2006;79(2):52.
43. Ramelteon (Rozerem) for insomnia. Med Lett Drugs Ther. 2005;47(1221):89-91.
44. Takeda Pharmceuticals. Ramelton (Rozerem). Available at: http://www.rozerem.com/images/PI.pdf. Accessed January 17, 2006.
45. Ezopiclone (Lunesta). Available at: http://wmf.lunesta.com/ PostedApprovedLabelingTextpdf. Accessed January 17, 2006.
46. Eszopicione (Lunesta) a new hypnotic. Med Lett Drugs Ther. 2005;47(1203):17-19.
47. Bristol-Meyers Squibb. Atazanavir (Reyataz). Available at: www.reyataz.com/managehiv/reyataz/dtc/index. jsp?BV_UseBVCookie=Yes. Accessed January 17, 2006.
48. GlaxoSmithKline. Fosamprenavir (Lexiva). Available at: http://us.gsk.com/products/assets/us_lexiva.pdf. Accessed January 17, 2006.
49. Sanofi-Aventis. Telithromycin (Ketek). Available at: http://products. sanofi-aventis.us/ketek/ketek.pdf. Accessed January 17, 2006.
50. Preskorn SH, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development. J Psych Prac. 2002;8(3):170-177.
51. Gram L. Fluoxetine. N Engl J Med 1994;331(20):1353-1361.
52. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy in general practice: differences between practitioners. Br J Gen Pract. 1999;49(440):195-198.
53. Holm M, Olesen F. Prescription of psychopharmaceuticals in general practice. 1. A registry study in the country of Arhus. Ugeskr Laeger. 1989;151(34):2122-2126.
54. Shad MU, Carmichael CA, Preston SH, Horst WD. The nature and extent of polypharmacy in patients on antidepressants as a function of teatment setting. Clin Pharmacol Ther. 1999;65:183.
55. Wolf ME, Bukowski ED, Conran J, Sirotovskaya L, Kagan V, Mosnaim AD. Polypharmacy: a problem of the decade of the nineties. Presented at 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Florida.
56. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the veterans Affairs Healthcare System: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1):5-15.
57. Silkey B, Preskorn SH, Golbeck A, Shah R, Neff M, Jones TL et al. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract. 2005;11(1):16-26.
58. Preskorn SH. Multiple medication use in patients seen in the Veterans Affairs healthcare system: so what? J Pschiatr. 2005;11(1):46-50.
59. Preskorn SH. Applied Clinical Psychopharmacology. Available at: www.preskorn.com. Accessed January 17, 2006.
60. Preskorn SH. Outpatient Management of Depression. 2nd ed. Caddo, OK: Professional Communications, Inc; 1999.
61. Book reviews. Mayo Clin Proc. 1998;4:392.
62. Coulehan JL, Schulberg HC, Block MR, Janosky JE, Arena VC. Depressive symptomatology and medical comorbidity in a primary care clinic. M J Psychiatry Med. 1990;20:335-347.
63. Fulop G, Strain JJ, Stettin G. Congestive heart failure and depression in older adults; Clinical course and health services use 6 months after hospitalization. Psychosomatics, 2003;44(5):367-373.
64. Robertson MM, Trimble MR. Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24(suppl 2):109-116.
65. Kupfer DJ, Frank E. Comorbidity in depression. Acta Psychiatr Scand Suppl. 2003;(418):57-60.
66. Levenson JL, Hamer RM, Rossiter LF. Relation of psychopathology in general medical inpatients to use and cost of services. Am J Psychiatry. 1990;147:1498-1503.
67. Badamgarav E, Weingarten SR, Henning JM, et al. Effectivness of disease management programs in depression: A systematic review. Am J Psychiatry. 2003;160(12):2080-2090.
68. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-226.
69. Chisholm D, Diehr P, Knapp M, et al. Depression status medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry. 2003;183:121-131.
70. Series HG. Drug treatment of depression in medically ill patients. J Psychosom Res. 1992;36:1-16.
71. Evans D. Antidepressant adverse effects and antidepressants in the medically ill. Am Soc Clin Psychopharm Progress Notes. 1995;6:22-25.
72. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61(1):9-15.
73. United States Food and Drug Administration Center for Drug Evaluation and Research. New drug approval reports. Available at: http://www.fda.gov/cder/ rdmt/default.htm. Accessed January 17, 2006.
74. Phillips DP, Bredder CC. Morbidity and mortalityfram medical errors: an increasingly serious public health problem. Annu Rev Public Health. 2002;23:135-150. Epub 2001 Oct 25:135-150.
75. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681-1690.
76. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol. 1996;16(2):101-103.
77. Markowitz JS, DeVane CL The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacol Bull. 2001;35(1):53-64.
78. Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992;2(4):356-367.
79. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed. Caddo, OK: Professional Communications, Inc; 1996.
80. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract. 2003;9(5):376-383.
81. Preskorn SH, Lacey R. Polypharmacy: When is it rational? J Prac Psych and Behav Hlth. 1995;1:92-98.
82. Preston SH. Defining "is." J Prac Psych and Behav HHh. 1999;5(4):224-228.
83. Preskorn SH. De-spinning in vitro data. J Prac Psych and Behav Hlth. 1999;5(5):283-287.
84. Janicak PJ, Davis JM, Preskorn SH. Treatment with mood stabilizers. Principles and Practices of Psychopharmacology. Philadelphia, PA: Lippincott, Williams 4 Wilkins; 2001:369-381.
85. Janicak PJ, Davis JM, Preskorn SH, Ayd FJ, Jr. Treatment with mood stabilizers. Principles and Practice of Psychopharmacotherapy. Philadelphia: Lippincott, Williams & Wilkins; 2001:383-462.
86. Ragheb M, Ban TA, Buchanan D, Frolich JC. Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatry. 1980;41(11):397-398.
87. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):1-13.
88. Preskom SH. Drug development in psychiatry and genomics: From E.coli to man. J Psych Prac. 2001;7(6):415-419.
89. Preskorn SH. The human genome project and drug discovery in psychiatry: Identifying novel targets. J Psych Prac. 2001;7(2):133-140.
90. Preskorn SH. Why are CYP enzymes important when considering SSRI's. In: Clinical Pharmacology of Selective Serotonin Reuptake. Caddo, OK: Professional Communications; 1996;131-160.
91. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14(2):90-98.
92. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21(2):161-166.
93. Zimmer R. Relationship between tyramine potiation and monoamine oxidase (MAO) inhibition. Comparison between moclobemide and other MAO inhibitors. Acta Psychiatr Scand Suppl. 1990;360:81-83.
94. Preskom SH. Classification of neuropsychiatrie medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psych Prac. 2005;10(3):177-181.
95. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63-i01.
96. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6 week placebo controlled trial. Neuropsychopharmacology. 1999;20(5):491-505.
97. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87-96.
98. Leonard BE, Richelson E. Synaptic effects of antidepressants: Relation to their therapeutic and adverse effects. In: Buckley PF, Waddington JL, eds. Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Oxford, England: Butterworth-Heinemann; 1999:67-84.
99. Levy RH, Thummel KE, Trager WF, Hansten P, Eichelbaum M. Metabolic Drug Interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000.
100. Flockhart DA. Drug adverse reactions and interactions. In: Stein JH, Eisenberg JM, eds. Internal Medicine. St. Louis, IL. Mosby Publishing; 1998:265-269.
101. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115-121.
102. Side effects, interactions and warnings about herbs. Personal Health Zone. Available at: www.personal-healthzone.com/herbsafety.html. Accessed January 17, 2006.
103. HIV drug interactions. Available at: www.hiv-druginteractions.org. Accessed January 17, 2006.
104. HIV/AIDS treatment information. Project Inform's Drug Interactions. Available at: www.projinf.org/fs/drugin.html. Accessed January 17, 2006.
105. Grapefruit juice drug interactions. Powernet Design. Available at: www.powernetdesign.com/grapefruit. Accessed January 17, 2006.
106. U.S. Food and Drug Administration, National Consumers League, 1998. Food & Drug Interactions. Available at: http://vm.cfsan.fda.gov/~lrd/fdinter. html. Accessed March 9, 2006.
107. Drug Facts ami Comparisons 2006. St. Louis, IL: Walters Kluwer; 2006.
108. ePocrates. Available at: www.epocrates.com. Accessed January 6, 2006.
109. Hansten PD, Horn JR. Drue Facts and Comparisons. 2006. St. Louis, IL; Walters Kluwer; 2005.
110. P450 UGT and P-gp drug interactions. Mental Health Connections. Available at www.mhc.com/cytochromes/index.html. Accessed January 17, 2006.
111. Thomson MICROMEDEX.Thomson MICROMEDEX. Available at: www.micromedex.com. Accessed January 17, 2006.
112. Preskorn SH. Relating clinical trials to Psychiatric Practice: Part I: The case of a 13-year old on Aripiprazole and fluoxetine. J Psych Prac. 2003;9(4):307-313.
113. 2006 Physicians' Desk Reference (PDR): Your Complete Print and Electronic Drug Information Solution. 60th ed. Montvale, NJ: Thomson POR; 2005.
114. US Feed and Drug Administration. Medwatch. Available at: www.fda.gov/medwatch. Accessed March 9, 2006.
115. US Pharmacopeia. Available at: www.usp.org. Accessed March 9, 2006.